Th. van Nuijs, chief editor of the Revue Belge de Médecine Dentaire, interviews Professor Eric Fossion on the problematic of bisphosfonates and their role in the osteonecrosis of the jaws. Prof. Eric Fossion is maxillo-facial surgeon. Actually, he is professor part-time at the Catholic University of Leuven. He is Head Department of Dentistry, Oral and Maxillofacial Surgery, Middelheim Hospital, Antwerp.
Download full-text PDF |
Source |
---|
Head Neck
April 2013
Department of Obstetrics and Gynecology, Division Gynecologic Oncology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium.
Background: Due to its rarity, there is no standard treatment for tongue cancers that concur with pregnancy. Treatment depends on the stage of cancer, gestational age of the pregnancy, and the wish of the mother to maintain the pregnancy. The purpose of this study was to review the literature and to report 5 new cases.
View Article and Find Full Text PDFClin Nucl Med
January 2011
Departments of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.
Purpose Of The Report: identifying imaging predictors of healing of osteonecrosis of the jaw (ONJ) in cancer patients may assist in better stratification of treatment strategies.
Materials And Methods: patients with ONJ were followed prospectively and underwent bone scintigraphy, both planar and single-photon emission computed tomography (SPECT) imaging. End points were time to healing and the number of recurrences.
Oral Oncol
March 2010
Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium.
Bisphosphonates (BP) have been associated with the occurrence of osteonecrosis of the jaw (ONJ), possibly by causing an excessive bone turnover inhibition. However, little in vivo evidence exists to support this theory. The (99m)Tc-medronate scintigrams of patients with skeletal metastases and BP use (n=40) were individually matched with cancer patients without BP exposure (n=40) and controls with neither malignancy nor BP use (n=40).
View Article and Find Full Text PDFOncologist
February 2009
Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.
The introduction of bisphosphonates in oncology has dramatically changed the management of patients with metastatic bone disease. In this manuscript, we thoroughly scrutinize the available body of clinical trials supporting the use of bisphosphonates in this setting and review new and ongoing research. Additionally, we summarize the data showing the benefits of bisphosphonate use in the prevention of treatment-induced bone loss and the intriguing emerging evidence on the antitumor potential of some of these agents when used in the adjuvant setting.
View Article and Find Full Text PDFRev Belge Med Dent (1984)
June 2008
Th. van Nuijs, chief editor of the Revue Belge de Médecine Dentaire, interviews Professor Eric Fossion on the problematic of bisphosfonates and their role in the osteonecrosis of the jaws. Prof.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!